This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Novavax (NVAX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed at $234.29 in the latest trading session, marking a +0.2% move from the prior day.
Is iShares MSCI USA Equal Weighted ETF (EUSA) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for EUSA
Novavax (NVAX) Stock Surges YTD as COVID Vaccine Advances Well
by Zacks Equity Research
Upon approval and successful commercialization, Novavax's (NVAX) COVID-19 vaccine should reap huge revenues. The company's other pipeline candidates also show promise.
Novavax (NVAX) Begins Clinical Study on COVID/Flu Combo Jab
by Zacks Equity Research
Novavax (NVAX) starts enrolling patients in a phase I/II study to evaluate a combination of its COVID vaccine and seasonal influenza vaccine.
Pfizer (PFE) Begins Study on RSV Vaccine in Older Adults
by Zacks Equity Research
Pfizer (PFE) starts a phase III study which will evaluate its respiratory syncytial virus vaccine candidate, RSVpreF in adults aged 60 years and above.
3 Large Biotech Stocks Worth Adding to Your Portfolio
by Zacks Equity Research
REGN, MRNA & VRTX are the three biotech companies that are likely to outperform the sector on the back of strong fundamentals.
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna, Johnson & Johnson and Novavax
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna, Johnson & Johnson and Novavax
3 COVID Vaccine Makers to Watch on Pfizer Jab Full FDA Approval
by Zacks Equity Research
Stocks of coronavirus vaccine makers BNTX and MRNA fly high following complete approval of Pfizer's COVID-19 vaccine. The momentum is likely to continue for these stocks. JNJ is another strong contender in this field.
Is iShares MSCI USA Equal Weighted ETF (EUSA) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for EUSA
Why Novavax (NVAX) Stock Fell 19% on Friday
by Madeleine Johnson
Shares of the biotech firm plunged 19.6% in Friday trading after it delayed U.S. submission for its Covid-19 vaccine for the third time.
Novavax's (NVAX) Q2 Loss Widens, Revenues Miss, Shares Down
by Zacks Equity Research
Novavax (NVAX) reports wider-than-expected loss in the second quarter of 2021 while revenues also miss estimates. Shares down in after-hours trading.
Novavax (NVAX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Novavax (NVAX) delivered earnings and revenue surprises of -26.33% and -19.63%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Novavax (NVAX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On Novavax's (NVAX) upcoming second-quarter earnings call, investor focus is likely to be on the company's progress with its COVID-19 vaccine candidate, NVX-CoV2373.
Analysts Estimate Novavax (NVAX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed at $207.19 in the latest trading session, marking a -1.58% move from the prior day.
5 Best Inverse/Leveraged ETF Areas of Last Week
by Sanghamitra Saha
Wall Street was subdued last week. A slew of earnings results for the second quarter and a new report on consumer spending for June came in stronger than expected. But increasing cases of the delta variant of COVID-19 also weighed on risk-on sentiments.
Novavax (NVAX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Novavax (NVAX) closed at $179.14, marking a +0.75% move from the previous day.
Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed at $188.59 in the latest trading session, marking a -0.55% move from the prior day.
Moderna (MRNA) Begins Dosing in Study on mRNA Flu Vaccine
by Zacks Equity Research
Moderna (MRNA) doses the first participant in a phase I/II study on its quadrivalent mRNA-based vaccine candidate, mRNA-1010, against seasonal influenza.
Vaccine Stocks Fall as Delta Becomes Dominant Variant in US
by Kinjel Shah
Per the latest CDC data, the Delta variant now makes up almost half of the COVID-19 cases in the United States.
Novavax (NVAX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Novavax (NVAX) closed at $217.22, marking a +0.68% move from the previous day.
Novavax (NVAX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed at $212.31 in the latest trading session, marking a +1.61% move from the prior day.
Novavax (NVAX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Novavax (NVAX) closed at $192.48, marking a +0.12% move from the previous day.
Novavax (NVAX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Novavax (NVAX) closed at $192.24, marking a -1.1% move from the previous day.
Biotech Stock Roundup: SAGE Declines on Data, Regulatory Updates From VRTX, ITOS
by Zacks Equity Research
The biotech sector was in focus last week with regulatory updates from Sage (SAGE) and Vertex (VRTX), among others.